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Executive summary
The World Health Organization (WHO) has identified mental health as an integral component of the 
COVID-19 response. Its rapid assessment of service delivery for mental, neurological and substance use 
(MNS) disorders during the COVID-19 pandemic, on which this report is based, is the first attempt to 
measure the impact of the pandemic on such services at a global level. The data were collected through 
a web-based survey completed by mental health focal points at ministries of health between June and 
August 2020. The questionnaire covered the existence and funding of mental health and psychosocial 
support (MHPSS) plans, the presence and composition of MHPSS coordination platforms, the degree of 
continuation and causes of disruption of different MNS services, the approaches used to overcome these 
disruptions, and surveillance mechanisms and research on MNS data. 
In total, 130 (67%) WHO Member States, across all WHO regions, submitted answers to the survey. Data 
were disaggregated by region, income group and stage of transmission of COVID-19. 
The vast majority, 116 or 89% of responding countries, reported that MHPSS response is part of their 
national COVID-19 response plans. However, only 17% of these countries have ensured full additional 
funding for MHPSS covering all activities. 
Two-thirds (65%) of responding countries have a multisectoral MHPSS coordination platform for COVID-19 
response, and more than 65% of these countries include the ministries of health, social/family affairs and 
education and also nongovernmental organizations as part of these platforms. 
Almost half (51%) of responding countries reported that ensuring the continuity of all MNS services was 
included in the list of essential health services in their national COVID-19 response plan, while 40% of 
countries reported the inclusion of some MNS services in the list of essential health services in their national 
response plan. 
To understand government policies on access to a range of MNS services, the status of closure of existing 
services was checked across different categories and settings. A total of 10 types of services for MNS 
disorders were included, such as inpatient and outpatient services at mental hospitals; outpatient 
services, inpatient psychiatric and neurological units as well as treatment of substance use disorders 
at general hospitals; and services for MNS disorders at primary health care, residential, home and day 
care services at community level. No country reported a full closure of all services; but in only 7% of 
responding countries were all services fully open, with 93% of countries reported disruptions in one or 
more of their services for MNS disorders. 
There were differences in the types of service affected by closure, with outpatient services in mental 
and general hospitals as well as community-based services predominantly more affected. For example, 
community-based services were more impacted compared with inpatient facilities, with full or partial 
closure in more than 40% of countries and home care and day care services reaching levels of full or partial 
closure in 60–70% of countries. 
Countries were also asked to report on disruption (complete or partial) of delivery of specific MNS 
interventions. For the purpose of the survey, complete disruption was defined as more than 50% of 
users not served as usual, and partial disruption as between 5% and 50% of users not served as usual. 
One-third (33%) of responding countries reported complete or partial disruption across at least 75% of 
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specific MNS-related interventions/services. This level of disruption was the highest within countries in the 
community transmission stage of COVID-19 (44%). 
An important finding is that some life-saving emergency and essential MNS services were reported as being 
disrupted; 35% of countries reported some disruption of management of emergency MNS manifestations 
(including status epilepticus, delirium and severe substance withdrawal syndromes) and 30% reported 
disruption in supply of medications for people with MNS disorders. 
Prevention and promotion mental health services and programmes were most severely affected. Around 
three-quarters of school mental health or workplace mental health services were wholly or partially 
disrupted. Approximately only 30% of mental health services for children and adolescents or for older adults 
were available with no disruption, and fewer than 40% of antenatal or postnatal mental health services 
were not disrupted. Almost 60% of all psychotherapy and counselling services were reported as partially 
disrupted. Overdose prevention and management programmes and critical harm reduction services were 
disrupted in more than 50% of countries.
The main causes of disruption were identified as a decrease in outpatient volume due to patients not 
presenting, travel restrictions hindering access to health facilities for patients and a decrease in inpatient 
volume due to cancellation of elective care. 
Community-based services and mental health prevention and promotion programmes, already limited in 
availability, are reported to be disrupted at a time when society needs them the most due to the adverse 
mental health impacts COVID-19. 
Countries have responded to the disruption of MNS services in multiple ways. Some 70% of countries have 
responded by using telemedicine/teletherapy to replace in-person consultations (this included use of any 
remote contact, such as telephone or video conferencing). Other measures that were reported include 
helplines for MHPSS (68%) and specific measures for infection prevention and control in mental health 
services (65%). Training in basic psychosocial skills for health care providers working in COVID-19 treatment 
centres was the most common approach in low-income countries (60%). Generally speaking, however, 
interventions such as task sharing through building the capacity of general health workers seem to be 
underutilized in many countries (38%). 
Slightly more than half of responding countries (53%) were reported to be collecting data on MNS disorders 
or manifestations in people with COVID-19, and two-thirds (66%) of countries reported ongoing or planned 
studies related to the impact of COVID-19 on mental health. A gap was identified in the areas of substance 
use and neurology research related to the pandemic. 
This report provides key insights into the extent of disruption of MNS services and measures being adopted 
in response. Certain limitations should be kept in mind when examining the results of this rapid assessment; 
these include the limitations associated with self-reported data, particularly concerning judgements often 
being made by a single focal point. 
The survey highlights the need to strengthen the monitoring of changes in service availability, delivery 
and utilization at country level, and to establish informed decision making on required adaptations and 
strategies for MNS services during the pandemic. WHO has published Maintaining essential health services: 
operational guidance for the COVID-19 context (1), which should be considered when making specific 
adaptations and considerations for safe delivery and restoration of MNS services, including emergency 
acute care and outpatient care guidance.  
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Key messages
• MHPSS is recognized by countries as an integral component of 
their COVID-19 response. Almost all countries reported that MHPSS is 
part of their national COVID-19 response plans. Two-thirds of countries have a 
multisectoral MHPSS coordination platform for COVID-19 response; however, 
most countries are lacking additional funding for MHPSS response plans.   
• Disruption of essential MNS interventions/services are reported 
in many countries. No country reported full closure of all MNS services, but 
a majority experienced some disruptions, including disruptions of essential, 
emergency and life-saving MNS services. Community-based outpatient services 
and prevention and promotion of mental health services, as well as services for 
specific age groups such as older adults and children, were among the most 
severely disrupted. 
• Learned lessons are emerging. Countries are responding to the 
disruption of MNS services in multiple innovative ways, including telemedicine, 
teletherapy interventions, hotlines and training for health care providers. 
Notable differences in responses to disruptions were observed between high-
income and low-income countries. 
• More data collection and research are required. Almost half 
of responding countries are not collecting any data on MNS disorders or 
manifestations in people with COVID-19, and fewer than one-tenth of countries 
are researching COVID-19 effects on brain health.
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Introduction
Throughout the world, people are affected by MNS disorders, at staggering rates. In many contexts, 
appropriate and evidence-based treatment is lacking and people with mental health conditions experience 
severe human rights violations, discrimination and stigma. In conflict and other humanitarian settings, 
where mental health conditions1 are especially common, these issues are even more pronounced. Yet, 
despite this, investment in mental health remains extremely limited, characterized by a lack of resources 
and services and a large treatment gap, especially in resource-limited settings (2–4).
There are direct and indirect consequences of COVID-19 on mental health conditions, leading to increased 
demand for services. In addition, health systems around the world are challenged, leading to the disruption 
of delivery of essential services, especially for the most vulnerable populations. Major stressors such as the 
COVID-19 pandemic represent risk factors for the development, exacerbation and relapse of a range of MNS 
disorders. Furthermore, COVID-19 itself is associated with neurological and mental complications, such as 
delirium/encephalopathy, agitation, stroke, insomnia, loss of sense of taste and smell, anxiety, depression 
and Guillain-Barré syndrome (5–8). 
Pre-existing MNS disorders increase the risk of becoming severely ill or of death, or of having long-term 
complications due to COVID-19 (9, 10). For example, people with dementia have a higher susceptibility 
to COVID-19 and higher rates of death associated with the disease (11–13). Many people are afraid of 
infection, of dying and of losing family members. People have been physically distanced from their social 
support networks, and many have lost those they love (14). Millions of people are facing economic turmoil, 
having lost or being at risk of losing their incomes and livelihoods (15). Many may be facing increased 
levels of alcohol and drug use or are engaging in addictive behaviours (16). There may be long-term mental 
or neurological consequences following COVID-19 infection, thus necessitating follow-up of patients and 
further research in this area (17–19).
The disruption of care for MNS disorders can be life-threatening, for example for treatment for epilepsy, 
unaddressed suicide risk, unmanaged opioid dependence leading to overdose, and severe alcohol 
withdrawal syndromes (20, 21). Additionally, not managing MNS disorders will hinder people’s recovery 
from COVID-19 through the potential inability of those living with mental disorders (either before, during 
or after the pandemic) to work or being trapped in a cycle of poor mental health and poor reintegration 
into communities (22).
WHO has identified mental health as an integral component in COVID-19 response (1, 23). MHPSS should 
be treated as an integral and cross-cutting component in public health emergency responses as part of a 
range of pillars/domains, such as case management, risk communication and community engagement, the 
continuation of health services, coordination within countries, and operations (e.g. staff support). Mental 
health is an integral part of universal health coverage and is crucial to the overall recovery of individuals, 
communities and countries after emergencies. 
Tracking access to health services during the pandemic is critical in order to achieve the optimal balance 
between fighting COVID-19 and maintaining these services. WHO’s recent pulse survey on continuity of 
essential health services during the pandemic provides insights and perspectives on its impact on up to 
25 essential health services in countries and how countries are adapting strategies to maintain essential 
services (24).
1  Mental health conditions include mental, neurological and substance use (MNS) disorders, suicide risk and associated 
psychosocial, cognitive and intellectual disabilities.
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In order to further understand the impact of COVID-19 on service delivery for MNS disorders, a specific 
survey was sent to designated mental health focal points in ministries of health of all Member States across 
six WHO regions. This rapid assessment of service delivery is the first attempt to measure the impact of the 
COVID-19 pandemic on MNS services at a global level. The survey covered the existence and funding of 
MHPSS plans, the presence and composition of MHPSS coordination platforms, the degree of continuation 
and causes of disruption of different MNS services, the approaches used to overcome these disruptions, 
and surveillance mechanisms and research on MNS data.
The results of the survey provide an overview of the impact of COVID-19 on MNS services and understanding 
of the reasons for disruptions. This information will inform planning and response to mitigate the effects by 
countries and regions. 
Methodology
The WHO Department of Mental Health and Substance Use developed the survey “Rapid assessment of 
service delivery for Mental, Neurological and Substance Use Disorders during the COVID-19 Pandemic” in 
collaboration with the six WHO regional offices. The survey followed the template of a recent WHO survey 
on the impact of COVID-19 on noncommunicable disease (NCD) resources and services (25), but adapted 
its structure and scope to mental health. The survey was drafted in English and translated into Chinese, 
French, Portuguese, Russian and Spanish, and was launched in mid-June 2020. 
Ministries of health were requested through WHO regional and country offices to appoint a focal point for 
completion of the survey. The focal point was encouraged to contact other experts in the country to obtain 
information relevant to answering the survey questions. Close contact with the focal points was maintained 
during their nomination and through submission of the questionnaire. WHO staff members in headquarters, 
regional and country offices were available to respond to enquiries, to provide additional guidance and to 
assist focal points in completing the survey questionnaire. In some regions and as requested, webinars 
were organized with focal points to provide further information on the survey and to respond to frequently 
asked questions. The survey was web-based, using the LimeSurvey platform, and countries were strongly 
encouraged to use this method for submission. An offline version of the questionnaire was made available 
whenever requested. Box 1 provides the thematic areas and questions of the survey. The full questionnaire 
is available in Annex 1.
Responses were received between 15 June and 15 August 2020,  though a handful of responses were 
accepted after this date (for the complete list of responding countries, see Annex 2). Fifty percent of responses 
were received during the month of July. When the WHO Secretariat received a completed questionnaire, 
the team reviewed it for incomplete and inconsistent answers. Respondents were re-contacted and asked 
for clarification and corrections as appropriate, to ensure data quality. Data from the national questionnaire 
were downloaded directly from the web-based platform into a spreadsheet and analysed using Statistical 
Package for the Social Sciences (SPSS) software.
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BOX 1. Survey thematic areas and questions
Is MHPSS response part of the national COVID-19 response plan?
Do multisectoral MHPSS coordination platforms for COVID-19 exist?
Q1
Q2
Mental health and psychosocial support
Is ensuring continuity of services for MNS disorders included in the list of essential health 
services as part of your country’s response during COVID-19?
During the COVID-19 pandemic, what are the government policies for access to essential 
services for MNS disorders at primary, secondary and tertiary care levels?
Q3
Mental, neurological and substance use services during the  
COVID-19 pandemic
Q4
Which of the following interventions/services related to MNS disorders have been disrupted 
due to COVID-19?
What are the leading causes of this disruption(s)?
Q5
Q6
What are the approaches used to overcome these disruptions?Q7
Is the ministry of health collecting or collating data on MNS disorders or manifestations in 
people with COVID-19?
Is there a planned or ongoing study related to the impact of COVID-19 on mental health/ 
brain health/substance use in the country (by government or anyone else, whether stand-
alone or as part of a broader survey)?
Q8
Q9
Surveillance and research concerning MNS disorders during the COVID-19 
pandemic
The analyses presented in this report are based on unweighted country data. Data were analysed by WHO 
regions and by World Bank income groups (based on classifications as of July 2020). Countries are classified 
among income groups according to 2019 gross national income (GNI) per capita, calculated using the 
World Bank Atlas method (low-income, US$ 1035 or less per capita; lower-middle-income, US$ 1036–4045; 
upper-middle-income, US$ 4046–12,535; and high-income, $12 536 or more) (26). 
Data were analysed also by the stage of COVID-19 transmission in responding countries (as of the middle 
timepoint of the survey on 15 July). COVID-19 transmission classification is based on a process of country 
self-reporting. Differing degrees of transmission may be present at the sub-national level; classifications are 
based on the highest category reported within a country. WHO has defined the following four transmission 
scenarios: No cases, countries with no cases; Sporadic cases, countries with one or more cases, imported or 
locally detected; Clusters of cases, countries experiencing cases, clustered in time, geographical location, 
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and/or by common exposure; Community transmission, countries experiencing larger outbreaks of local 
transmission, defined through an assessment of factors including, but not limited to large numbers of 
cases not linkable to transmission chains, large numbers of cases from sentinel laboratory surveillance 
or increasing positive tests through sentinel samples, multiple unrelated clusters in several areas of the 
country (27).
Certain limitations should be kept in mind when examining the results of this rapid assessment. Firstly, 
it is vital to acknowledge the limitations associated with self-reported data, particularly concerning 
judgements often being made by a single focal point. For some of the variables, it is not possible to compare 
self-reported responses with publicly available information due to the acute nature of the emergency 
and limited availability of data. While focal points were encouraged to consult with other stakeholders, 
especially other humanitarian responders, the extent to which a full range of consultation in each country 
has occurred is difficult to examine. Furthermore, this rapid assessment did not include other methods 
such as focus groups or interviews with key informants.
A further limitation is that most of the information provided relates to the country as a whole, thereby 
overlooking potentially significant variability within countries concerning, for example, rural versus urban 
areas or remote versus central parts of the country.
Additionally, the weakness of preexisting national information systems is another limitation. As per the 
WHO Mental Health Atlas 2017, only 37% of Member States regularly compile mental health-specific data 
covering at least the public sector. Additionally, 29% of WHO Member States compile mental health data 
as part of general health statistics (2). During the COVID-19 pandemic, we had to rely on preexisting 
information systems with their limitations to learn about the current impact on services. 
While the best attempts have been made to obtain information from all countries on all variables, 
some countries could not provide data for some questions, and some countries could not participate in 
the exercise within the time allowed. The most common reason for not participating in the exercise or 
for sending incomplete data was that focal points were engaged in the acute emergency response, as 
communicated by some countries and WHO country and regional offices. Also, in some cases the situation 
was changing rapidly, or sometimes the data available were difficult for countries to use to report the 
information in the manner requested in the survey. This could lead to potential bias in interpreting data 
at group level, such as WHO regions or World Bank income groups. This survey will be an ongoing activity 
for WHO, to be repeated regularly and integrated with the pulse survey on continuity of essential health 
services during the COVID-19 pandemic (24). 
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Table 1. Response rate by WHO region and World Bank income group
Results
In total, 130 (67%) WHO Member States responded to the survey between June and August 2020. Additional 
responses were obtained from 10 geographical territories. The current report includes the global analysis 
of data from Member States only. For a full list of responding countries, see Annex 2.
Overall, the survey had good representation across different income and geographical regions. The 
response rate varied between 50% and 90% across all WHO regions, with a high response rate in particular 
from countries in the Eastern Mediterranean, Americas and Western Pacific regions. The response rate 
across World Bank (WB) income categories was between 48% and 73% (Table 1). 
Total numbers 
of countries




WHO region AFR 47 28 60%
AMR 35 29 83%
EMR 21 19 90%
EUR 53 26 49%
SEAR 11 6 54%
WPR 27 22 81%
Income group Low 31 15 48%
Lower-middle 46 33 72%
Upper-middle 60 44 73%
High 57 38 67%
Total 194 130 67%
AFR: WHO African Region; AMR: WHO Region for the Americas; EMR: WHO Eastern Mediterranean Region; EUR: WHO European 
Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region
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Mental health and psychosocial support
The composite term “mental health and psychosocial support” is used in the Inter-Agency Standing 
Committee (IASC) Guidelines in Emergency Settings to describe “any local or outside support that 
aims to protect or promote psychosocial well-being or prevent or treat mental health condition” (28). 
The global humanitarian system uses the term MHPSS to unite a broad range of actors responding 
to emergencies such as the COVID-19 pandemic, including those working in health, social, education 
and community settings, as well as to “underscore the need for diverse, complementary approaches in 
providing appropriate support” (29). MHPSS is a cross-cutting matter of relevance to all emergencies 
and all sectors. While there is a need to have focused interventions with specific objectives and target 
groups, MHPSS needs a “whole of society” and “whole of government” approach. 
MHPSS as part of COVID-19 response plans
A remarkable majority, 116 or 89% of the responding countries, reported that MHPSS response was part of 
their national COVID-19 response plans (Fig. 1). However, only 17% of these countries have fully ensured 
additional funding for MHPSS response in the government budget for these plans, while 47% responded 
that they had secured partial funding (Fig. 2). The lack of funding by countries is a major concern and may 
reflect the inability of these countries to implement their existing COVID-19 MHPSS plans. 
While it was encouraging to note that more lower-income countries have MHPSS as part of their national 
COVID-19 response plan, the level of funding of such plans, whether full or partial, was greater for higher-
income groups. There is also regional variation in the integration of MHPSS into COVID-19 response 
plans. Regions with the largest number of preexisting humanitarian crises may be more familiar with the 
integration of MHPSS into their public health emergencies response, and these regions therefore show 
a higher number of countries reporting MHPSS being integrated into their COVID-19 response plans. At 
regional level, the Eastern Mediterranean and African regions show the highest percentage of countries 
reporting MHPSS integration in the response but with no additional funds allocated for this activity, 
followed very closely by the European and Americas regions (Fig. 1 and 2).
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Fig. 2.  Funding for MHPSS as part of COVID-19 response plans, by WHO region and  
WB income group
MHPSS multisectoral coordination
Two-thirds (65%) of responding countries have a multisectoral MHPSS coordination platform for 
COVID-19 response, with more than 50% across all regions and specifically more than 70% in the low-
income group (Fig. 3). The ministry of health is a member of the MHPSS coordination platform in 98% of 
countries, while 65% of countries include ministries of social/family affairs and education, and 68% include 
nongovernmental organizations (NGOs) as members of the coordination platform. This positive finding 
shows the commitment of a number of relevant line ministries to MHPSS. However, in more than 50% of 
countries, entities responsible for substance use were not part of the MHPSS multisectoral coordination 
platform. 
One-third (34%) of responding countries reported having no MHPSS coordination platform. This may reflect 
fragmentation of the MHPSS response in these countries, or a limited number of MHPSS multisectoral 
actors. While the results show a promising and widespread existence of MHPSS platforms in a majority of 
countries, the engagement of representatives of service user groups was reported in fewer than 40% of 
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Mental, neurological and substance use services during the  
COVID-19 pandemic
Despite the transition in many high-income countries towards psychiatric wards in general hospitals 
and the provision of community-based services, there are still a minimal number of facilities for 
community-based mental health care throughout the world, as evident from WHO Mental Health Atlas 2017 
data (2). Even before the COVID-19 pandemic, levels of public expenditure on mental health were minimal 
in low- and middle-income countries. Government expenditure on mental health was less than US$ 1 per 
capita in low- and lower-middle-income countries, whereas high-income countries spent more than US$ 
80 per capita. The majority of spending was going to mental hospitals, which serve a small proportion 
of those who need care. In low-income countries, the rate of mental health workers can be as low as two 
per 100 000 population, compared with more than 70 in high-income countries (2). During the COVID-19 
pandemic, and at a time when MNS services are needed on a large scale, many countries are dealing with 
a challenging situation with scarce preexisting resources and investment in this area. 
Inclusion of services for MNS disorders in the list of essential health services
More than half (51%) of countries reported “inclusion of all services for MNS disorders in the list of essential 
health services” as part of their country’s response during COVID-19, while 40% of countries reported 
inclusion of some MNS services; 9% reported no inclusion of MNS services within essential health services. 
In the African and Eastern Mediterranean regions, services for MNS disorders are not included in the list 
of essential health services in approximately 15% of countries. The inclusion of MNS services in essential 
health services shows an apparent discrepancy across income groups, with no inclusion reported more 
frequently by Member States in the lower-income groups (Fig. 5). It is also important to note that mental 
health services are lacking across many settings in general. 
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Fig. 5.  Countries including services for MNS disorders in the list of essential health services, by 
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Policies for access to essential services for MNS disorders
Countries were also asked about national-level governmental policies on access to essential services for MNS 
disorders. These included 10 settings and categories of service for MNS disorders: inpatient and outpatient 
services at mental hospitals; outpatient services, inpatient psychiatric and neurological units as well as 
treatment of substance use disorders at general hospitals; and primary health care, residential, home and day 
care services at community level. In the analysis, countries were classified into three groups: (i) “all types of 
services fully open” when every existing service was reported as being fully open; (ii) “one or more services 
disrupted” when at least one of the 10 services examined was reported as being either fully or partially closed; 
and (iii) “all types of services fully closed” if all existing services were reported as being fully closed.
No country reported full closure of all 10 categories of service for MNS disorders as described above. 
However, all services were fully open in just 7% of countries, while 93% of countries reported some 
disruption to their services for MNS disorders. 
No country in the Americas, Eastern Mediterranean or South-East Asia regions reported having all services 
fully open (Fig. 6). 
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When looking at each of the 10 different categories of services, there were marked differences in the type 
of service affected by closure, with outpatient services in both mental and general hospitals as well as 
community-based services being in the main more affected (Fig. 7). 
Around 70% of responding countries reported that inpatient services at mental hospitals and psychiatric 
units in general hospitals remained fully open. Neurology inpatient units, uniquely dealing with a wide range 
of life-saving interventions including for COVID-19 manifestations, were reported as being partially closed in 
more than 30% of countries. In contrast, inpatient services for substance use disorders were the most affected 
among all mental health inpatient services, with services fully closed in 12% of countries and partially closed in 
30% of countries. These findings are consistent with the recent WHO survey on NCD services, which reported 
that access to inpatient NCD services was generally less affected compared with outpatient NCD services (25). 
Approximately 60% of responding countries reported either partial or complete disruption of home or 
community outreach services (including social care services) for people with MNS disorders. For community-
based services, only residential and primary health care services were open in more than 50% of countries, 
while day care services were open in just over 30% of countries.
Outpatient services in mental hospitals and general hospitals were fully open in fewer than 60% of responding 
countries, while they were fully closed in 1% of countries at mental hospitals and 4% at general hospitals. A 
similar finding was made in the recent WHO survey on NCD services, with 59% of countries reporting that 
access to outpatient services was restricted to some degree, including 4% reporting total closure (25).
Fig. 7.  Policies for access to essential services for MNS disorders, by setting and  
categories of services
Note:  The difference in the denominator seen in Fig. 7 is due to the fact that in some countries these services are either non-
existent or information is not available. Thus at mental health hospitals 10% of countries did not report on policies for 
inpatient services for MNS disorders and 11% for outpatient services; at general hospitals 9% of countries did not report 
on policies for psychiatric inpatient units, 24% for neurology inpatient units, 20% for inpatient units for substance use 
disorders and 9% for outpatient services; and at the community-based level 33% did not report on residential services, 
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Disruptions in outpatient services at general hospitals were also more widespread in higher-income 
groups of countries, with services partially open in 17% of countries in the low-income group, around 
45% in the lower- and upper-middle-income groups and 60% in the high-income group (Fig. 9).
Fig. 9.  Policies for access to outpatient services for MNS disorders at general hospitals, by WB 
income group 
Disruptions in outpatient services at mental hospitals seem to be linked to the stage of transmission 
of the virus (27), with countries in the community stage showing the highest level of disruption, with 
services partially open in 47% of countries, around 40% within the clusters and sporadic stages, and 
fewer than 30% of outpatient services either fully closed or partially open in countries in the “no cases” 
group. Analysing the differences across income groups, outpatient services at mental hospitals were 
disrupted in a higher proportion of countries in the high-income group, with full closure or services 
partially open in more than 60% of them. In comparison, the figure was around 40% for upper- and 
lower-middle-income countries and 15% for the low-income group (Fig. 8). 
Fig. 8.  Policies for access to outpatient services for MNS disorders at mental hospitals, by WB 
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The recent WHO pulse survey on continuity of essential health services included one overlapping item 
on treatment for mental health disorders, which were reported to be disrupted in 61% of countries, with 
3% of those countries reporting severe/complete disruptions (24). The type of services for treatment of 
mental health disorders in this pulse survey, however, was not defined.
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Disruption of MNS-related interventions/services due to COVID-19
Countries were also asked about the level of disruption of 16 specific MNS-related interventions or 
services (Table 2), defining complete disruption as more than 50% of users not being served as usual 
and partial disruption as between 5% and 50% of users not being served as usual. We also looked at the 
level of disruption combined across the 16 specific MNS-related interventions/services. In the analysis, 
“Disruption in at least 75% of MNS-related interventions/services” was defined as 12 to 16 of the specific 
MNS-related interventions or services being reported as either completely or partially disrupted.
Table 2. List of specific MNS-related interventions/services
a.  Management of emergency MNS manifestations (including status epilepticus, delirium, severe substance 
withdrawal syndromes)
b. Psychotherapy/counselling/psychosocial interventions for MNS disorders 
c. Medicines for MNS disorders 
d. Psychosocial interventions for caregivers of people with MNS disorders 
e. Home or community outreach services (including social care services) for people with MNS disorders 
f. Mental health interventions during antenatal and postnatal period
g.  Services for children and adolescents with mental health conditions or disabilities, including develop-
mental disabilities
h. Services for older adults with mental health conditions or disabilities, including dementia 
i. Diagnostic and laboratory services for people with MNS disorders
j. Surgery for neurological disorders (e.g. epilepsy)
k. School mental health programmes
l. Work-related mental health programmes
m. Suicide prevention programmes
n. Overdose prevention and management programmes (e.g. naloxone distribution)
o. Critical harm reduction services (e.g. needle exchange programmes, outreach services)
p. Opioid agonist maintenance treatment of opioid dependence (with methadone or buprenorphine)
In almost one-third (33%) of countries, at least 75% of MNS-related services were completely or partially 
disrupted. This percentage was higher in particular for the African region (57%), as well as for countries in 
the community stage of transmission. High-income countries showed a lower level of disruption at 24% 
compared with the other income groups (Fig. 10). 
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Fig. 10.  Disruption in at least 75% of MNS-related interventions/services, by WHO region, WB 






























































Importantly, some life-saving emergency and essential MNS services were reported as being disrupted: 
35% of countries reported disruption of management of emergency MNS manifestations (including 
status epilepticus, delirium, severe substance withdrawal syndromes) and 30% reported disruption of 
medications for people with MNS disorders (Fig. 11).
Prevention and promotion mental health services and programmes were most severely affected and 
disrupted. Around three-quarters of school mental health or workplace mental health services were fully 
or partially disrupted.
Other MNS-related interventions/services with complete disruption in more than 20% of countries were 
suicide prevention programmes (24%), home or community outreach services (24%) and interventions 
for caregivers (21%).
At a time when they are highly needed, mental health services for the most vulnerable were reported to be 
disrupted. Less than 30% of countries reported no disruption to children’s and adolescent mental health 
services. In 70% of countries, MNS services for older adults were disrupted (56% partially disrupted, 14% 
completely disrupted). Fewer than 40% of antenatal or postnatal mental health services were not disrupted. 
Almost 60% of all psychotherapy and counselling services were reported as being partially disrupted. 
Laboratory monitoring of some psychotropic medications, such as clozapine and lithium, is an essential 
part of management for severe mental health conditions. More than 40% of countries reported disruption 
of laboratory services at mental health facilities.
14The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment
Fig. 11. Disruptions of MNS-related interventions/services due to COVID-19.
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Among interventions or services related to substance use, critical harm reduction services were 
completely disrupted in 30% of countries and partially disrupted in 35%; opioid agonist maintenance 
treatment of opioid dependence was completely disrupted in 27% of countries and partially disrupted 
in 18%; and overdose prevention and management programmes were completely disrupted in 21% of 
countries and partially disrupted in 32%. 
One in three countries at least partially closed down neurology inpatient units during the pandemic 
(33% partially closed, 2% fully closed), with surgeries for neurological disorders disrupted in two-
thirds of the countries (42% partially disrupted, 25% completely disrupted) and the management of 
emergency conditions such as status epilepticus being at least partly disrupted in one-third of countries 
(30% partially disrupted, 6% completely disrupted).
Causes of disruptions in MNS-related interventions/services
The survey not only included questions on disruptions of MNS-related interventions and services but 
also on the main causes of the reported disruptions. The leading causes of disruption were a decrease in 
outpatient volume due to patients not presenting (62% of countries), travel restrictions hindering access 
to health facilities (54%) and a decrease in inpatient volume due to cancellation of elective care (47%) 
(Table 3). Indeed, the same main reasons for disruption were identified in the recent WHO pulse survey on 
continuity of essential health services, as a combination of demand factors on one side, such as patients 
not presenting to outpatient care or perceptions that government or public transport lockdowns were 
hindering access, and on the other side supply factors such as cancellation of elective care or redeployment 
of clinical staff to provide COVID-19 relief (24).
When data were disaggregated across income groups, travel restrictions were reported as the most 
common cause of disruption for 73% of low-income countries (Fig. 12). Travel restrictions, together with 
limited availability and closure of community-based mental health services closer to where people live, can 
potentially lead to adverse outcomes for people with MNS disorders. 
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Decrease in outpatient volume due to patients not presenting 62.3 %
Travel restrictions hindering access to the health facilities for patients 53.8 %
Decrease in inpatient volume due to cancellation of elective care 46.9 %
Closure of outpatient services as per health authority directive 33.8 %
Closure of outpatient disease specific consultation clinics 33.1 %
Clinical staff related to MNS disorders deployed to provide COVID-19 relief 31.5 %
Insufficient staff to provide services 31.5 %
Insufficient Personal Protective Equipment available for health care providers 27.7 %
Closure of population level programs 24.6 %
Unavailability of health products at health facilities 23.8 %
The clinical set up has been designated as COVID-19 care facility 19.2 %
Inpatient services/hospital beds not available 12.3 %































Repurposing of staff or of facilities was also reported as a cause of disruption. An insufficient number of 
health workers or redeployment of mental health care staff to support COVID-19 facilities seems to be the 
cause of service disruption in nearly 30% of countries, while in 19% of countries the cause was using mental 
health facilities as a COVID-19 quarantine or treatment facility.
In 28% of countries respondents reported insufficient supplies of personal protective equipment (PPE) 
available for health care providers to provide services at mental health facilities; this was reported most 
frequently in the African region (43% of countries), followed by the Western Pacific Region (36%) (Fig. 13). 
Additionally, limited supplies of health products were reported as a cause of disruption in 24% of countries. 
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Fig. 13.  Insufficient personal protective equipment available for health care providers to provide 





































Approaches to overcome disruptions
Countries responded via a checklist on approaches being used to overcome service disruptions for the 
management of MNS disorders and to provide mental health and psychosocial support. A country could 
check multiple options. Quite a few measures are being applied, with the most frequent approaches 
being telemedicine/teletherapy used to replace in-person consultations (70% of countries). This included 
use of any remote contact such as telephone or video conferencing. Other measures used included 
helplines for MHPSS (68%) and specific measures for infection prevention and control in mental health 
services (65%) (Table 4). These findings are consistent with the recent WHO pulse survey on continuity of 
essential health services, which also identified telemedicine among the most frequent approaches (24).
Across regions and income groups, MHPSS helplines, specific measures for infection prevention and 
control, and triaging to identify priorities were consistently used as the most common approaches for 
overcoming disruption; whereas training in basic psychosocial skills for health care providers working 
in COVID-19 treatment centres was the most frequently used approach among the low-income group, 
reported in 60% of countries (Fig. 14). The use of technology in overcoming service delivery disruptions 
varies by income group. While more than 80% of high-income countries reported deployment of 
telemedicine/teletherapy to replace in-person consultations, or the use of helplines, both modalities 
were used in fewer than 50% of low-income countries (Fig. 15). An overview of global figures indicates 
that interventions such as task shifting/role delegation or building the capacity of general health 
workers on basic psychosocial skills and community outreach seem to be underutilized as intervention 
modalities compared with remote support methods. Recruitment of additional counsellors and new 
dispensing approaches for medications were among the least reported approaches. 
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Table 4. Approaches for overcoming disruptions in MNS-related intervention/services
Approaches
Percentage of  
countries (n=130)
Tele-medicine /tele-therapy deployment to replace in person consultations 70.0
Helplines established for mental health and psychosocial support 67.7
Specific measures for infection prevention and control in mental health services 65.4
Self-help or digital format of psychological interventions 53.8
Triaging to identify priorities 49.2
COVID-19 health care providers trained in basic psychosocial skills 44.6
Discharge or redirection of patients to alternate health care facilities 44.6
Task shifting / role delegation 37.7
Home or community outreach services 33.1
Novel supply chain / dispensing approaches for medicines for MNS disorders 32.3
Recruitment of additional counsellors 20.8
Fig. 14.  Approaches for overcoming disruptions in MNS-related intervention/services among the 
WB low-income group
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Surveillance and research concerning MNS disorders during the 
COVID-19 pandemic
Information, evidence and research are critical ingredients for appropriate mental health planning and 
response during any emergency, especially in novel situations such as the COVID-19 pandemic. The 
generation of new knowledge through research enables plans and actions to be based on evidence and 
best practice, and the availability of timely and relevant information or surveillance frameworks enables 
implemented actions to be monitored and improvements as well as gaps in service provision to be 
identified (30).
Data collection on MNS disorders or manifestations 
Data are needed to monitor trends and improve the quality of services during the pandemic through 
informed decision making. However, as shown by this survey, more than 40% of health ministries are 
not collecting any data on MNS disorders or manifestations in people with COVID-19. Across regions and 
income groups, more than 60% of countries in the South-East Asia and Western Pacific regions report 
collecting such data, while the proportion is less than 50% in low-income countries (Fig. 16).
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Fig. 17. Studies related to the impact of COVID-19 on MNS, by WB income group 
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Countries were also requested to report on any planned or ongoing study related to the impact of 
COVID-19 on mental health/brain health/substance use in the country, either by government or other 
stakeholders. In all, 66% of countries reported studies related to the impact of COVID-19 on mental 
health, brain health or substance use, with the most frequent type of study being on mental health 
impact (65% of countries). Across income groups, 80% of high-income countries reported carrying out 
studies on mental health impact. The number of countries globally conducting research on neurological 
or substance use was much lower (5% and 15% respectively) (Fig. 17 and 18). 
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This survey provides insights from mental health focal points within ministries of health on the extent of 
disruptions to services for mental, neurological and substance use disorders, and an indication of their 
experience in adopting strategies to mitigate the impact on service provision. There were differences 
in the type of services disrupted, with already scarce outpatient and community mental health services 
predominantly more affected. Mental health prevention and promotion programmes felt the most severe 
impacts at a time when countries need them the most. While acknowledging the limitations of such a 
survey, including the limitations of a self-reported questionnaire, the results, however, clearly indicate that 
mental health systems  have been compromised at a time when they are likely needed most. 
Innovative methods are being applied in many countries through teleservices and helplines; however, 
limited resources are a challenge to using these tools in lower-resource settings. Tools such as task sharing 
through building the capacity of general health workers seem to be underutilized. Although global 
advocacy for mental health inclusion in COVID-19 responses has resulted in better integration into plans, 
multisectoral coordination platforms and regular data collection, there is still a gap in the financial and 
human resources allocated to integrate mental health into the emergency response, which constitutes a 
significant challenge and a barrier to the continuity of services. The COVID-19 pandemic emphasizes the 
value of including MHPSS not only in response to emergencies and recovery, but also before emergencies 
through integrating measures into preparedness plans and efforts (31).
WHO’s interim guidance Maintaining essential health services: operational guidance for the COVID-19 context 
(1) includes a section with specific adaptations and considerations for safe delivery of MNS services covering 
emergency acute care, outpatient care guidance and other contexts (see Annex 3). While many countries 
are implementing WHO-recommended strategies to mitigate disruptions to services, more information is 
needed to identify which approaches work in different settings during the different phases of the pandemic. 
Decisions about the nature and timing of adaptations to service delivery must be informed using accurate 
and timely data. As the pandemic is likely to ebb and flow over the coming months, real-time monitoring 
of changes in mental health service delivery and utilization is needed. 
Conclusion
21The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment
1. Maintaining essential health services: operational guidance for the COVID-19 context. Interim 
guidance. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/WHO-
2019-nCoV-essential-health-services-2020.1, accessed 2 October 2020). 
2. Mental health atlas 2017. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/
handle/10665/272735/, accessed 2 October 2020), 
3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national 
incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries 
and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet. 2018;392(10159):1789–858 (https://www.thelancet.com/journals/lancet/article/PIIS0140-
6736(18)32279-7/fulltext, accessed 2 October 2020). 
4. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P et al. Scaling-up treatment of 
depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016; 3: 415–24 (https://
www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(16)30024-4/fulltext, accessed 2 October 2020). 
5. Clinical management of COVID-19: interim guidance. Geneva: World Health Organization; 2020 (https://
www.who.int/publications/i/item/clinical-management-of-covid-19, accessed 2 October 2020). 
6. Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med; 2020 (https://
www.nejm.org/doi/full/10.1056/NEJMp2008017, accessed 2 October 2020). Epub 2020/04/14. 
7. Liang L, Ren H, Cao R, Hu Y, Qin Z, Li C et al. The effect of COVID-19 on youth mental health. Psychiatr 
Q. 2020 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173777/, accessed 2 October 2020).
8. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A et al. Neurological associations of 
COVID-19. Rapid review. Lancet Neurol. 2020;19(9):767–83 (https://www.thelancet.com/journals/
laneur/article/PIIS1474-4422(20)30221-0/fulltext, accessed 2 October 2020). 
9. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61-62 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138334/, accessed 2 October 2020).
10. Li L, Li F, Fortunati F, Krystal JH. Association of a prior psychiatric diagnosis with mortality among hospitalized 
patients with coronavirus disease 2019 (COVID-19) infection. JAMA Netw Open. 2020;3(9):e2023282 (https://
jamanetwork.com/journals/jamanetworkopen/fullarticle/2771037, accessed 2 October 2020). 
11. Bianchetti A, Rozzini R, Guerini F, Boffelli S, Ranieri P, Minelli G et al. Clinical presentation of COVID19 
in dementia patients. J Nutr Health Aging; 2020 (https://europepmc.org/backend/ptpmcrender.
fcgi?accid=PMC7227170&blobtype=pdf, accessed 2 October 2020). 
12. Hwang JM, Kim JH, Park JS, Chang MC, Park D. Neurological diseases as mortality predictive factors 
for patients with COVID-19: a retrospective cohort study. Neurol Sci. 2020 41:2317–24 (https://link.
springer.com/article/10.1007/s10072-020-04541-z, accessed 2 October 2020). 
13. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess deaths from COVID-19 and other 
causes, March–April 2020. JAMA. 2020 324(5):510–3 (https://jamanetwork.com/journals/jama/article-
abstract/2768086, accessed 2 October 2020). 
14. Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing: 
the need for prevention and early intervention. JAMA Intern Med. 2020;180(6):817–8 (https://
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2764404, accessed 2 October 2020).
15. Dohrenwend BP. The role of adversity and stress in psychopathology: some evidence and its 
implications for theory and research. J Health Soc Behav. 2000;41(1):1–19 (https://www.jstor.org/
stable/2676357, accessed 2 October 2020). 
16. Inter-Agency Standing Committee Reference Group on Mental Health and Psychosocial Support. 
Guidance on operational considerations for multisectoral mental health and psychosocial support 
programmes during the COVID-19 pandemic. Geneva: Inter-Agency Standing Committee; 2020 
(https://interagencystandingcommittee.org/iasc-reference-group-mental-health-and-psychosocial-
support-emergency-settings/iasc-guidance, accessed 2 October 2020). 
References
22The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment
17. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P et al. Psychiatric and neuropsychiatric 
presentations associated with severe coronavirus infections: a systematic review and meta-analysis 
with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–27 (https://www.
thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30203-0/fulltext, accessed 2 October 2020).  
18. Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M et al. Long-term consequences of 
COVID-19: research needs. Lancet Infect Dis. 2020;20(10):1115–7 (https://www.thelancet.com/
journals/laninf/article/PIIS1473-3099(20)30701-5/fulltext, accessed 2 October 2020). 
19. Rimmer A. Covid-19: impact of long term symptoms will be profound, warns BMA. BMJ. 
2020;370:m3218 (https://www.bmj.com/content/370/bmj.m3218, accessed 2 October 2020). 
20. Assenza G, Lanzone J, Brigo F, Coppola A, Di Gennaro G, Di Lazzaro V et al. Epilepsy care in the time 
of COVID-19 pandemic in Italy: risk factors for seizure worsening. Front Neurol. 2020 (https://www.
frontiersin.org/articles/10.3389/fneur.2020.00737/full?report=reader, accessed 2 October 2020). 
21. Sharma M, Lioutas VA, Madsen T, Clark J, O’Sullivan J, Elkind MSV et al. Decline in stroke alerts and 
hospitalisations during the COVID-19 pandemic. Stroke Vasc Neurol. 2020;0 (https://svn.bmj.com/
content/svnbmj/early/2020/08/20/svn-2020-000441.full.pdf, accessed 2 October 2020). doi:10.1136/
svn-2020-000441. 
22. Policy brief: COVID-19 and the need for action on mental health. New York: United Nations; 2020 
(https://unsdg.un.org/sites/default/files/2020-05/UN-Policy-Brief-COVID-19-and-mental-health.pdf, 
accessed 2 October 2020).
23. Adhanom Ghebreyesu T. Addressing mental health needs: an integral component of COVID-19 
response (editorial). World Psychiatry. 2020;19:2 (https://onlinelibrary.wiley.com/doi/full/10.1002/
wps.20768, accessed 2 October 2020). 
24. Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report, 
27 August 2020. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/
WHO-2019-nCoV-EHS_continuity-survey-2020.1, accessed 2 October 2020). 
25. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results 
of a rapid assessment. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/
item/ncds-covid-rapid-assessment, accessed 2 October 2020). 
26. Country classification. Washington (DC): World Bank Group; 2020 (https://datahelpdesk.worldbank.
org/knowledgebase/topics/19280-country-classification, accessed 2 October 2020). 
27. WHO coronavirus disease (COVID-19) dashboard. Transmission classification (15 July 2020). Geneva: 
World Health Organization; 2020 (https://covid19.who.int/, accessed 16 July 2020). 
28. Inter-Agency Standing Committee Reference Group on Mental Health and Psychosocial Support in 
Emergency Settings. Guideline on mental health and psychosocial support in emergency settings. 
Geneva: Inter-Agency Standing Committee; 2007 (https://interagencystandingcommittee.org/iasc-
task-force-mental-health-and-psychosocial-support-emergency-settings/iasc-guidelines-mental, 
accessed 2 October 2020).
29. Inter-Agency Standing Committee Reference Group on Mental Health and Psychosocial Support. 
Interim briefing note addressing mental health and psychosocial aspects of COVID-19 outbreak. 
Geneva: Inter-Agency Standing Committee; 2020 (https://interagencystandingcommittee.org/iasc-
reference-group-mental-health-and-psychosocial-support-emergency-settings/interim-briefing, 
accessed 2 October 2020).
30. Comprehensive mental health action plan 2013–2020. Geneva: World Health Organization; 2013 
(https://apps.who.int/iris/handle/10665/89966, accessed 2 October 2020).
31. Gray B, Hanna F, Reifels L. The integration of mental health and psychosocial support and disaster risk 
reduction: a mapping and review. Int J Environ Res Public Health. 2020;17(6):1900 (https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC7142938/, accessed 2 October 2020). 
23The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment
Annex 1 : Questionnaire
31 
 




Rapid assessment of service delivery for Mental, Neurological and 
Substance Use Disorders during the COVID 19 Pandemic 
 
Department of Mental Health and Substance Use 
World Health Organization 
 
 




In the context of the COVID-19 pandemic response, we are reaching out to you to ask a small set of questions to 
quickly assess how essential services for mental, neurological and substance use (MNS) disorders are being 
impacted in your country by the current pandemic in order to help plan WHO support and technical tools which 
might be of value. We may reach out to you to seek any clarifications if needed. We will be using the aggregated 
data only for reporting purposes. Should we decide later to use examples or case studies that identify specific 
countries, we will contact you to request advance permission. Since these questions are intended to support a 
rapid situation assessment on these issues, we would be grateful to receive your responses by 30 June 2020. 
Please click on the link below to access the survey. Note that you may access the questionnaire as often as 
needed, saving your responses as you go. We believe that it will take you 20 minutes to respond to these 
questions.  
 





Information on those who completed the questions  
Who is the focal point who provided the responses?  
Name: ________________________________  
Position: ______________________________  
Organization: __________________________  
Country: ______________________________  
Email: ________________________________  
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POLICIES AND PLANS 
1. Is mental health and psychosocial support response part of national COVID-19 response plan? 
a. Yes 
b. No 
c. Don’t know 
 
1i. If yes, is additional funding allocated for mental health and psychosocial support in the government budget 
for the COVID-19 response plan? 
a. Yes and 100 % funded 
b. Yes but only partially funded 
c. No, not funded 
d. Don’t know 
 




c. Don’t know 
 
2i. If yes, are the following Ministries and bodies part of the coordination platform?  
(Please check all boxes that apply) 
a. Ministry of Health 
b. Ministry of Social/Family Affairs 
c. Ministry of Education 
d. Ministry of Finance 
e. Ministry of Foreign Affairs 
f. United Nations Agencies 
g. Governmental entity responsible for substance use 
h. International non-governmental Organizations 
i. Non-governmental Organizations  





3. Is ensuring continuity of services for mental, neurological and substance use (MNS) disorders included in the 
list of essential health services as part of your country’s response during COVID-19? 
a. Yes, all 
b. Yes, some 
c. No/not yet 
d. Don’t know 
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4. During the COVID-19 pandemic, what are the government policies for access to essential services for mental, 
neurological and substance use (MNS)disorders at primary, secondary and tertiary care levels?  
 
Please answer for different categories of services for mental, neurological and substance use disorders. Please 
provide the response for national level policies. 
 




[ ] Outpatient services 
are open 
[ ] Outpatient services 
are partially open  
[ ] Outpatient services 
are closed 
[ ] Don’t know 
[ ] Not Applicable 
 
Inpatient services 
[ ] Inpatient services 
are open 
[ ] Inpatient services 
are partially open (eg 
for emergencies only) 
[ ] Inpatient services 
are closed 
[ ] Don’t know 




Outpatient services for 
MNS disorders 
[ ] Outpatient services 
for MNS disorders 
open 
[ ] Outpatient services 
for MNS disorders 
partially open 
[ ] Outpatient services 
for MNS disorders 
closed 
[ ] Don’t know 
[ ] Not Applicable 
Psychiatric inpatient 
unit 
[ ] Psychiatric inpatient 
unit open 
[ ] Psychiatric inpatient 
unit partially open 
[ ] Psychiatric inpatient 
unit closed 
[ ] Don’t know 




[ ] Neurology 
inpatient unit open 
[ ] Neurology 
inpatient unit 
partially open 
[ ] Neurology 
inpatient unit closed 
[ ] Don’t know 
[ ] Not Applicable 
 
Inpatient units for 
substance use 
disorders 
[ ] Inpatient units 
for substance use 
disorders open 
[ ] Inpatient units 
for substance use 
disorders partially 
open 
[ ] Inpatient units 
for substance use 
disorders closed 
[ ] Don’t know 
[ ] Not Applicable 






Day care services 
[ ] Day care services 
open 
[ ] Day care services 
partially open 
[ ] Day care services 
closed 
[ ] Don’t know 
[ ] Not Applicable 
Home care services 
[ ] Home care services 
open 
[ ] Home care services 
partially open 
[ ] Home care services 
closed 
[ ] Don’t know 
[ ] Not Applicable 
Services for MNS 
disorders in primary 
health care (PHC) 
services 
[ ] Services for MNS 
disorders in primary 
health care (PHC) 
services open 
[ ] Services for MNS 
disorders in primary 
health care (PHC) 
services partially 
open 
[ ] Services for MNS 
disorders in primary 
health care (PHC) 
services closed 
[ ] Don’t know 
[ ] Not Applicable 
Residential services 
(e.g. care homes) 
[ ] Residential 
services open 
[ ] Residential 
services partially 
open 
[ ] Residential 
services closed 
[ ] Don’t know 





5. Which of the following interventions/services related to mental, neurological and substance use (MNS) 
disorders have been disrupted due to COVID-19?  
Please check all that apply with their level of disruption 
Mental, neurological and substance use 
(MNS) disorders interventions/services 
Completely disrupted 
(more than 50% of 
clients not served as 
usual) 
Partially disrupted 
(5% to 50% of 
clients not served 
as usual) 
Not disrupted 
(less than 5% 
of clients not 
served as 
usual)  
a. Management of emergency MNS 
manifestations (including status epilepticus, 
delirium, severe substance withdrawal 
syndromes) 
[ ] [ ] [ ] 
b. Psychotherapy/counseling/psychosocial 
interventions for MNS disorders  
[ ] [ ] [ ] 
c. Medicines for MNS disorders  [ ] [ ] [ ] 
d. Interventions for caregivers of people with 
MNS disorders  
[ ] [ ] [ ] 
e. Home or community outreach services [ ] [ ] [ ] 
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(including social care services) for people 
with MNS disorders  
f. Mental health interventions during 
antenatal and postnatal period 
[ ] [ ] [ ] 
g. Services for children and adolescents with 
mental health conditions or disabilities, 
including developmental disabilities 
[ ] [ ] [ ] 
h. Services for older adults with mental 
health conditions or disabilities, including 
dementia  
[ ] [ ] [ ] 
i. Diagnostic and laboratory services for 
people with MNS disorders 
[ ] [ ] [ ] 
j. Surgery for neurological disorders  
(e.g. epilepsy) 
[ ] [ ] [ ] 
k. School mental health programme [ ] [ ] [ ] 
l. Work-related mental health programme [ ] [ ] [ ] 
m. Suicide prevention programme [ ] [ ] [ ] 
n. Overdose prevention and management 
programs (e.g. naloxone distribution) 
[ ] [ ] [ ] 
o. Critical harm reduction services (e.g., 
needle exchange programs, outreach 
services) 
[ ] [ ] [ ] 
p. Opioid agonist maintenance treatment of 
opioid dependence (with methadone or 
buprenorphine)  




6. What are the main causes of this disruption(s)? (Please check all that apply) 
 
a. Closure of outpatient services as per health authority directive 
b. Closure of outpatient disease specific consultation clinics as per health authority directive 
c. Closure of population level programs as per health authority directive 
d. Decrease in outpatient volume due to patients not presenting 
e. Decrease in inpatient volume due to cancellation of elective care 
f. Inpatient services/hospital beds not available 
g. Insufficient staff to provide services 
h. Clinical staff related to mental, neurological and substance use disorders deployed to provide COVID-19 clinical 
management or emergency support 
i. The clinical set up has been designated as COVID-19 care facility 
j. Insufficient Personal Protective Equipment (PPE) available for health care providers to provide services 
k. Unavailability/Stock out of essential medicines, medical diagnostics or other health products at health facilities 
l. Travel restrictions hindering access to the health facilities for patients 
m. Others (please specify what are the other causes of this disruption): 
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7. What approaches are being used to overcome the service disruptions to the management of mental, 
neurological and substance use disorders and provide mental health and psychosocial support in health 
facilities? (Please check all that apply) 
a. Tele-medicine /tele-therapy deployment to replace in-person consults 
b. Self-help or digital format of psychological interventions 
c. Task shifting / role delegation 
d. Novel supply chain and/or dispensing approaches through other channels for medicines for mental, 
neurological and substance use disorders 
e. Triaging to identify priorities 
f. Redirection of patients to alternate health care facilities or discharge to their homes/families 
g. Home or community outreach services 
h. Recruitment of additional counsellors  
i. Helplines established for mental health and psychosocial support  
j. Health care providers working in COVID-19 treatment centres trained in basic psychosocial skills  
k. Implementation of specific measures for infection prevention and control in mental health services 




8. Is the Ministry of Health collecting or collating data on mental, neurological and substance use disorders or 
manifestations in people with COVID-19?  a. Yes b. No c. Don’t know 
 
9. Is there a planned or ongoing study related to impact of COVID-19 on mental health/ brain health/substance 
use in the country (by government or anyone else, whether stand-alone or as part of a broader survey). Please 
check all that apply and provide details.  
a. Yes, on mental health impact b. Yes, on neurological disorders or brain health 
c. Yes, on alcohol d. Yes, on psychoactive drugs 
e. Yes, on addictive behaviours f. No 
g. Don’t know  
 
10. Please upload any files related to your mental health and COVID-19 response in your country that you would 
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Annex 2
List of responding countries and territories
WHO Member States
Member State WHO region Responding focal point
Afghanistan EMR Bashir Ahmad Sarwari
Algeria AFR Mohamed Chakali 
Andorra EUR Josep Romagosa Massana, Joan Escoter Blavi
Antigua and Barbuda AMR Teri-Ann Joseph
Argentina AMR Hugo Barrionuevo
Armenia EUR Armine Aghajanyan
Australia WPR Leila Jordan
Austria EUR Christina Dietscher
Bahamas AMR Phillip Swann
Bahrain EMR Eman Ahmed Haji
Bangladesh SEAR Helal Uddin Ahmed
Barbados AMR Brian MacLachlan
Belgium EUR Pol Gerits
Belize AMR Iveth Quintanilla
Benin AFR François Agossou
Bolivia (Plurinational State of ) AMR Maria Guadalupe Gonzales Gonzales
Bosnia and Herzegovina EUR Drazenka Malicbegovic
Botswana AFR Moagi Gaborone
Brazil AMR Catarina Maglhães Dahl
Brunei Darussalam WPR Raidah Mohamed
Bulgaria EUR Hristo Hinkov
Burkina Faso AFR Marie Emmanuelle Zoure
Burundi AFR Jérôme Ndaruhutse
Cabo Verde AFR Aristides Delgado da Luz
Cambodia WPR Chhit Sophal
Cameroon AFR Justine Laure Menguene Mviena 
Canada AMR Marie-Anik Gagné
Chile AMR Matías Irarrázaval
China WPR Fu Jun
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Member State WHO region Responding focal point
Colombia AMR Nubia Esperanza Bautista Bautista
Congo AFR Rosalie Likibi-boho  
Cook Islands WPR Evangelene Wong
Côte d'Ivoire AFR Anna-Corinne Bissouma 
Cuba AMR Carmen Borrego Calzadilla
Czech Republic EUR Dita Protopopová
Denmark EUR Nicola Elisabeth Petersen
Dominican Republic AMR Alexandra Rodríguez
Ecuador AMR Ignacia Paez
Egypt EMR Eman Gaber
Equatorial Guinea AFR Ana Bella Ekiri Nguie 
Eritrea AFR Theodros Tekeste
Ethiopia AFR Dereje Assefa Zewude
Fiji WPR Miliakere Nasorovakawalu
Finland EUR Helena Vorma
Germany EUR Thomas Stracke
Ghana AFR Akwasi Osei
Grenada AMR Meryl Roberts-Marryshow
Guinea AFR Kémo Soumaoro 
Guyana AMR Util Richmond-Thomas
Honduras AMR Carolina Padilla Rivera
Hungary EUR Robert Wernigg
Indonesia SEAR Prianto Djatmiko
Iran (Islamic Republic of ) EMR Ahmad Hajebi
Iraq EMR Emad Abdulrazaq Abdulghani
Ireland EUR Michael Murchan
Jamaica AMR Kevin Goulbourne
Japan WPR Takuro Kushima
Jordan EMR Fateen Janim
Kazakhstan EUR Negai Nikolai
Kenya AFR Simon Njuguna, Mercy Karanja
Kiribati WPR Arite Katherine Torote
Kuwait EMR Najah Mohammed Alenezi
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Member State WHO region Responding focal point
Lao People's Democratic Republic WPR Bouathep Phoumin
Latvia EUR Ilze Straume
Lebanon EMR Rabih El Chammay
Liberia AFR Angie Tarr Nyakoon
Libya EMR Ali Abdalla Abdusamad
Lithuania EUR Jurgita Kinderiene
Madagascar AFR Glenn Torrencelli Edosoa
Malaysia WPR Nurashikin Bte Ibrahim
Maldives SEAR Aminath Shahuza
Mali AFR Cheickna Tounkara
Malta EUR Antonella Sammut
Marshall Islands WPR Marita Edwin
Mexico AMR Lorena Rodríguez Bores Ramírez
Monaco EUR Eric Voiglio
Mongolia WPR Khandarmaa Tseren-Ochir
Montenegro EUR Aleksandra Ražnatović
Morocco EMR Bouram Omar
Myanmar SEAR Tin Oo
Namibia AFR Magdalena Didalelwa
New Zealand WPR Barry Welsh
Nicaragua AMR Joaquín Antonio Escoto Galeano
Nigeria AFR Benjamin Aiwonodagbon
Niue WPR Sione Lima Mavaetangi
North Macedonia EUR Lence Miloseva
Norway EUR Anna Villa
Oman EMR Amira Al Raidan
Pakistan EMR Samra Mazhar
Panama AMR Jose Alberto Calderon
Papua New Guinea WPR Umadevi Ambihaipahar
Paraguay AMR Luis Armando Taboada Renna
Peru AMR Yuri Licinio Cutipe Cárdenas
Philippines WPR Frances Prescilla Cuevas
Poland EUR Karolina Konarzewska
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Member State WHO region Responding focal point
Qatar EMR Susan Clelland
Republic of Moldova EUR Jana Chihai
Russian Federation EUR Irina Borisovna Moroz
Saint Kitts and Nevis AMR Cherrilyn Warde Crawford
Saint Lucia AMR Alicia St Juste
Saudi Arabia EMR Eisha Mohammed Gaffas
Senegal AFR Jean Augustin Diegane Tine
Seychelles AFR Gina Michel
Sierra Leone AFR Kadiatu Savage
Singapore WPR Ong Lay Tin
Slovenia EUR Matej Vinko
Solomon Islands WPR Paul orotaloa
Somalia EMR Zeynab Ahmed Noor
South Africa AFR Ad Shiba
South Sudan AFR Joseph Mogga
Sri Lanka SEAR Rohan Rathnayake
Sudan EMR Zienat  Sanhori
Suriname AMR Savora Omanette
Thailand SEAR Tanpisth
Togo AFR Kolou Dassa
Tonga WPR John Lee Taione
Trinidad and Tobago AMR Subrena Calvin-Smith
Tunisia EMR Fatma Charfi
Turkmenistan EUR Glory
Tuvalu WPR Katalina Filipo
Ukraine EUR Sergii Shum
United Arab Emirates EMR Muna Alkuwari
United States of America AMR Leandra Olson
Uruguay AMR Horacio Porciuncula
Vanuatu WPR Jimmy Obed
Venezuela  
(Bolivarian Republic of )
AMR Lía Rodríguez Sánchez
Viet Nam WPR Tran Trung Ha
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Note:  Although care has been taken to include names of all contributors, information on any omissions or inaccuracies can be 
communicated to WHO Secretariat at mhatlas@who.int.
AFR: WHO African Region; AMR: WHO Region for the Americas; EMR: WHO Eastern Mediterranean Region; EUR: WHO European 
Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region.
Member State WHO region Responding focal point
Yemen EMR Abdulquddos Abdulwahab Harmmal
Zambia AFR John Mayeya
Zimbabwe AFR SM. Chirisa
Areas and territories
Area or territory WHO region Responding focal point
Aruba AMR Chris Goedhart
Bermuda AMR Preston Swan
British Virgin Islands AMR Virginia Rubaine
Cayman Islands AMR Janett Flynn and Dympna Carten
Curaçao AMR Beulah Mercera
Hong Kong SAR (China) WPR Edmund Fong Ho Ching 
Macao SAR (China) WPR Chi-Veng Ho
Northern Mariana Islands WPR Jesse R. Aguon
occupied Palestinian territory, including  
east Jerusalem EMR Samah Jabr
Turks and Caicos Islands AMR Alicia Malcolm
AFR: WHO African Region; AMR: WHO Region for the Americas; EMR: WHO Eastern Mediterranean Region; EUR: WHO European 
Region; SAR: Special Administrative Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region.
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Annex 3
Modifications for safe delivery of MNS services and considerations 
towards restoration of activities1
Programme 
activities











Continue acute and emergency care for MNS disorders (e.g. 
imminent suicide risk, seizures, delirium, acute psychosis, acute 
mania, opioid overdose, severe and complicated substance 
withdrawal syndromes), and ensure that some inpatient care for 
MNS disorders remains available. 
Since neurological manifestations are associated with 
COVID-19 (e.g. delirium or encephalopathy, agitation, stroke, 
meningoencephalitis, impaired sense of smell or taste), ensure 
that all patients presenting with these manifestations are 







Prioritize face-to-face care for initial management of severe 
MNS disorders involving either severely impaired functioning 
or life-threatening situations. 
Establish clear protocols to ensure the availability of 
diagnostic and laboratory testing for key scenarios (e.g. 
to determine cause of delirium or interactions between 
medicines, blood level of lithium, white blood cell count for 
clozapine use, neuroimaging for stroke). 
Incorporate early recognition of and treatment for antenatal 
and postnatal MNS disorders into modified ANC and PNC 
protocols. See also Section 2.2.1. 
For people with substance use disorders, maintain critical 
harm reduction interventions and psychosocial services, 
including uninterrupted opioid agonist maintenance 
treatment and management of severe withdrawal 
syndromes. 
Reach out to frontline workers in all health facilities 
(including staff in long-term care homes) to offer access to 
mental health care and self-help materials. 
Introduce use of longer prescription periods involving 
either expanded take-home practices (e.g. for methadone 
or buprenorphine treatment, sustained release antiseizure 
medicines, or neuroleptic depot with informed consent) or 
periodic delivery of medicines to the home. Involve caregivers 
to ensure medicines are stored safely to reduce suicide risk. 
Reinstate routine 
laboratory monitoring 
for people with MNS 
disorders on psychotropic 
medications on return to 
the clinic. 
Prepare for increased 
service use (beyond 
pre-pandemic levels) for 
a range of conditions, 
including depressive 
disorder, anxiety 
disorder, alcohol and 




disorder and self-harm 
and suicidality.
 Ensure that 
rehabilitation support 
is available for 
people with severe 




1  Reproduced from section 2.2.3 of Maintaining essential health services: operational guidance for the 
COVID-19 context. Interim guidance (1).
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Programme 
activities




Digital health care or telemedicine can be introduced for:  
• follow-up visits;  
• psychological treatments, if functioning is not severely 
impaired; 
• caregivers of people with MNS disorders;  
• group psychosocial care (e.g. mutual-help groups). 
Redirect initial care for mild depression and anxiety to self-
help (e.g. digital or written materials) (2). 
Enhance outreach care for isolated people with severe MNS 
disorders, as needed. Ensure home visits are maintained 
for specific situations (e.g. care of older adults with MNS 
disorders). 


















Limit admissions to urgent cases. Perform COVID-19 testing 
prior to admission, ensuring that recommended quarantine 
protocols are followed with full IPC used for positive cases. 
Establish and enhance monitoring of complaint mechanisms 
for neglect or human rights violations. Enable remote family 
support if visiting is suspended. Use accessible formats and 
familiar communication channels to deliver information 
about IPC measures for people with psychosocial, intellectual 
or cognitive disabilities. Ensure that access to high-quality 
treatment and criteria for isolation are the same for people 










Enhance engagement with governmental and NGO actors 
to mobilize social and resources to support people with 
MNS disorders (e.g. at home, and in schools, care homes and 
prisons), and ensure that people with severe MNS disorders 
have access to services that address their basic needs.
Modify school mental health services to be delivered 
through online platforms
Consider long-term 
effects of COVID-19 
response on risk groups 
(pre-existing MNS 
disorders, older adults, 
women, young people, 
children); enhance 
cross-sectoral services.
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Programme 
activities










Provide access to information about positive coping 
methods.
Support nurturing learning environments for children and 
young people who are confined at home.
Support activities that help isolated older adults stay 
connected with others. older adults stay connected.
ANC: antenatal care; IPC: infection prevention and control; MNS: mental, neurological and substance use; 
NGO: nongovernmental organization; PNC: postnatal care.  
1. Maintaining essential health services: operational guidance for the COVID-19 context. Interim 
guidance. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/WHO-
2019-nCoV-essential-health-services-2020.1, accessed 2 October 2020).  
2. Doing what matters in times of stress: an illustrated guide. Geneva: World Health Organization; 2020 
(https://apps.who.int/iris/ handle/10665/331901, accessed 2 October 2020).
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